Business / Finance

RSS

Medidata Solutions second quarter net revenues increase 25% to $50.2 million

Medidata Solutions, a leading global provider of SaaS-based clinical technology solutions that enhance the efficiency of clinical development, today announced its financial results for the second quarter 2011, as well as provided financial guidance for the third quarter and full year 2011.

9 Aug 2011

PHT total revenues increase 10% for first half of 2011

PHT Corporation completed its most successful Q2 in company history on June 30, 2011. The strong, outstanding results reflect the growing worldwide adoption of its market-leading ePRO Systems.

9 Aug 2011

Gilead to acquire Genentech's OCP facility, other process development assets

Gilead Sciences, Inc. today announced that the company has signed a definitive agreement under which Gilead will purchase a clinical biologics manufacturing facility and certain process development assets located in Oceanside, California from Genentech, a member of the Roche Group.

9 Aug 2011

K-V sells assets of Nesher to Zydus and Zynesher Pharmaceuticals

K-V Pharmaceutical Company today announced the completion and closing of the previously announced sale of assets of Nesher Pharmaceuticals, Inc., the Company's wholly-owned generic subsidiary, and the Company's generic business and assets to Zydus Pharmaceuticals (USA), Inc and Zynesher Pharmaceuticals (USA) LLC.

9 Aug 2011

Lexicon's second quarter revenues decrease 55% to $0.6 million

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2011.

9 Aug 2011

HUYA enters strategic partnership with King's Lab

HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovations, today announced a strategic partnership with the Shanghai Jiao Tong University School of Pharmacy King's Lab. The alliance with HUYA will assist King's Lab in accelerating the development of their novel drugs to international standards.

8 Aug 2011

A.P. Pharma second quarter net loss decreases to $1.9 million

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2011 and highlighted its recent corporate progress.

8 Aug 2011

Symphony announces acquisition of JGI

Symphony Corporation, a global healthcare technology solutions provider, today announced the acquisition of JGI, a New Jersey-based Human Capital Management consulting and technology firm with a significant presence in the healthcare industry nationally.

8 Aug 2011

Response Genetics second quarter total revenue increases 18.8% to $6.7 million

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results and business progress for the second quarter ended June 30, 2011.

8 Aug 2011

Kaan Medikal to distribute Saladax's My5-FU diagnostic test in Turkey

Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Kaan Medikal will serve as the exclusive distributor of Saladax's My5-FU diagnostic test throughout the Turkish market.

8 Aug 2011

Eagle Hospital Physicians announces acquisition of Inpatient Management

Expanding geographical presence and capabilities, Eagle Hospital Physicians today announced the acquisition of Inpatient Management Incorporated (IMI), a hospitalist management company based in St. Louis, Mo.

8 Aug 2011

Chemed board declares increased quarterly cash dividend

Chemed Corporation announced today that the Board of Directors has declared a quarterly cash dividend of 16-cents per share on the Company's capital stock, payable on September 6, 2011, to shareholders of record as of August 16, 2011. This is a 2-cent, or 14.3%, increase over the 14-cent dividend paid in the second quarter of 2011.

8 Aug 2011

American Shared Hospital Services first half 2011 revenues increase 4.0% to $8,573,000

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the second quarter and first half of 2011.

8 Aug 2011

AMRI second quarter total revenue increases 9% to $53.9 million

AMRI today reported financial and operating results for the second quarter ended June 30, 2011.

8 Aug 2011

Inhibitex second quarter net loss decreases to $5.3 million

Inhibitex, Inc. today announced its financial results for the second quarter ended June 30, 2011 and provided an update on several recent clinical and corporate developments.

8 Aug 2011

Most leading health plans see enrollment gains in first quarter 2011

Most of the nation's leading health plans saw enrollment gains in the first quarter of 2011 and all saw improved profit margins both year-over-year and for the quarter, a promising start for 2011. Between December 2010 and March 2011 top plans saw an aggregate increase of more than 2.0 million members. While aggregated fully-insured business continued to experience losses, the administrative services only (ASO) segment gained over 2.2 million members during the primary 2011 open enrollment season.

8 Aug 2011

BioScrip second quarter revenue increases 7.1% to $441.4 million

BioScrip, Inc. today announced 2011 second quarter financial results. Second quarter revenue for the period ended June 30, 2011, was $441.4 million with a net loss of $2.3 million, or $0.04 per share, including $8.7 million in restructuring charges and a legal settlement. Excluding the after tax effect of these charges, the Company earned $0.10 per diluted share. Adjusted EBITDA for the second quarter was $18.1 million.

8 Aug 2011

Unigene second quarter revenue decreases to $2.5 million

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced second quarter financial results for the period ended June 30, 2011. The Company highlighted significant progress achieved in the second quarter with the continued execution of its turnaround strategy.

8 Aug 2011